What top creators are saying about Hims & Hers Health, Inc.(HIMS)— Page 2

Referenced as the pairing narrative for the Boner meme token which reached $90M.

Tokenized synthetic weekend trading pairs deviate significantly from real-market closing prices, exposing retail liquidity providers to recurring Monday institutional arbitrage losses.

Noted as having a $6B market capitalization and used as a benchmark valuation comparison

Targeted by speculative MemeFi social trading tokens characterized by insider momentum and rapid liquidity shifts.

Mentioned as a $7 billion market cap stock connected to the BONER token narrative.

Tokenized shares are utilized as real-world asset pairings with meme coins on the Robinhood chain ecosystem.

Purchased as synthetic stock using trading transaction fees generated by satirical meme coin pairs.

Exhibiting strong market presence at a $6 billion market cap, driven by elevated internet search volume for peptides.

Tokenized HIMS stock paired with memecoins on AMMs is driving on-chain premium pricing and liquidity provisioning yields.

Subjected to indiscriminate growth stock selling pressure despite maintaining an organically growing, recession-resistant business detached from interest rate impacts.

Could benefit as companies openly embrace stock-backed meme communities; viewed as a highly convex trade at current prices where investors might regret not holding a small position in the coming weeks.

Subject to artificial equity supply constraints as tokenized shares are locked into on-chain meme coin liquidity pools.

Facilitating friction-free telehealth access to high-demand GLP-1 weight-loss medications, expanding recurring subscription revenue and customer base.

Closed at $28.84 on the NYSE but surged to around $39 (a 37% premium) in onchain tokenized trading due to limited inventory and a float squeeze.

Presents a long-term hyper-growth opportunity in digital health where current valuation does not fully reflect international expansion, GLP-1 distribution, or high-margin product rollouts, though investors should expect continued share price volatility.

Broad-market basket selling has disconnected the stock from its underlying business performance and low-risk balance sheet, creating a buying opportunity in a recession-resistant business.

Viewed as consistently undervalued with strong fundamentals, strong Rule of 40 score, and high-margin upside from GLP-1 drug expansion and future peptide approvals.

The 10% sell-off driven by recycled reports regarding customer returns is a market overreaction with minimal financial impact (~$75,000), offering a value buying opportunity at fundamentally cheap valuation levels.

Placed into Visa's acquirer monitoring program due to elevated subscription chargebacks and cancellations, compounded by high 30%-40% short interest.

Traded up 3.5% as broader healthcare and pharmaceutical names benefited from sector rotation.

Gained 13% as macro liquidity flows lifted high-growth risk-on assets; maintained as a top conviction holding.

Demonstrated significant positive momentum supported by broader inflows into the healthcare sector.

Short-term macro pressure is disconnecting the share price from solid fundamentals, creating a long-term growth opportunity in off-patent GLP-1 and peptide commercialization.

Strong Q2 results with 38% YoY revenue growth, expanding subscriber base reaching nearly 3 million, and strong long-term potential driven by new specialties like TRT and peptides, alongside AI personalization.

Strong top-line growth and subscriber additions demonstrate healthy underlying business momentum, but investors must monitor operating expenses and legal costs.

Long-term outlook is viewed as very positive, acting as an all-in-one healthcare platform for small-to-medium health problems that bypasses traditional insurance, though caution is advised before earnings due to high volatility.

Mentioned as a comparable stock that is more expensive than Real Brokerage.

Positioned as the clear winner-take-most leader in the telehealth and digital pharmacy space with high projected forward revenue growth and massive scale advantages.

Working through a correction phase that may be nearing its end, with upcoming news announcements regarding peptides suggesting potential re-engagement opportunities.

Acquired a peptide compounding facility and positioned itself for the peptide market, acting as a speculative play on telehealth.

Experienced a price drop due to an FTC lawsuit, but legal proceedings will take years while business catalysts like GLP-1s and international growth remain robust.

Sold off sharply to the $27-$29 range, viewed as an irrational reaction since healthcare subscription services are recession-resistant with strong recurring revenue.

Maintains a strong medium-term trend and is considered a high-beta growth play tied to consumer trends in peptides and alternative health treatments.

Dropped significantly due to disappointment and market skepticism regarding its peptide business expansion.

Increasingly trading based on peptide regulation news and FDA announcements rather than traditional telemedicine fundamentals.

The stock is considered undervalued at 3x gross profit despite 35% revenue growth and a 50% market share in U.S. telehealth. Current 'Peptide FUD' and analyst downgrades are viewed as a temporary mispricing of a high-growth disruptor.

Chart printing a bullish fractal; linked to the growing consumer biotech theme.

Noted as a successful play within the peptide and telehealth space.

Very undervalued; analyst recommends using macro-driven dips as a buying opportunity.

Identified as a hyper-growth stock currently being punished by market sentiment despite consistent revenue growth and improving fundamentals.

Reached a 6-month high of $37 following a successful analyst call at $18.

Experienced a 4X gain followed by a crash to previous lows; serves as a warning of high-growth stock volatility.

Showing resilience and growth, benefiting from a broader biotech and healthcare bid.

Lacks the scale to defend its intellectual property against giants like Eli Lilly.

Aggressively capturing demand for GLP-1 weight loss medications like Wegovy.

Viewed as very cheap despite a recovery from previous massive drawdowns; cited as a high-growth asset requiring patience.

Used as a case study for contrarian investing; stock has doubled recently despite previous negative social media sentiment.

Positioned as a leader in the GLP-1 market with a high-growth subscription model that bypasses insurance friction; viewed as undervalued with significant upside from international expansion and new peptide products.

Expanding into the high-demand GLP-1 weight loss market with offerings like Wegovy.

Market is ignoring growth from GLP-1 medications and the Eucalyptus acquisition; trading at an irrational discount despite pristine fundamentals.